Head & Neck Cancers | Specialty

Frontline Durvalumab Fails to Improve OS in Recurrent or Metastatic HNSCC

February 5th 2021

February 5, 2021 - Durvalumab failed to improve overall survival over the EXTREME chemotherapy regimen in the frontline treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma with tumors expressed high levels of PD-L1, missing a primary end point of the phase 3 KESTREL trial.

Rationale for Sequencing in Second Line

February 4th 2021

LIBRETTO-001 Phase 1/2 Trial Overview

February 4th 2021

Advice for Managing RAI-Refractory DTC

January 28th 2021

Molecular Testing in Treatment Selection

January 28th 2021

Search Continues for Agents to Provide Additive Benefit to Chemoradiation in Head and Neck Cancer

January 21st 2021

Nabil F. Saba, MD, FACP, discusses the results of the JAVELIN Head and Neck 100 trial, as well as data from other key, recent studies in head and neck cancer.

Sorafenib and Lenvatinib Side Effect Profile and Dosing

January 21st 2021

RAI-Refractory DTC Trials: Phase 3 DECISION and SELECT

January 21st 2021

28-Gene Score May Predict Distant Metastatic Recurrence in Advanced Head and Neck Cancers

January 18th 2021

Although the ability to treat head and neck cancer has certainly improved over the years, a significant percentage of patients experience recurrent disease after initial treatment.

Multidisciplinary Management for the Treatment of DTC

January 18th 2021